Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07210632) titled 'Window Trial of Fluorescently Labeled Nivolumab (Nivo800) in High Grade Glioma (HGG)' on Sept. 29.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).
Primary Sponsor: Eben Rosenthal
Condition:
Brain Cancer
HGG
Glioma
High Grade Glioma
High Grade Gliomas
High Grade Glioma (III or IV)
High Grade Glioma (HGG) of the Brain With BRAF Aberration
Intervention:
Drug: Nivolumab
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: January 1, 2026
Target Sample Si...